Nouriel Niamehr, DO
Physical Medicine & Rehabilitation · Encino, CANPI 1679881346
Payments from drug & device makers
Across 264 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- IBSA Pharma Inc.$2K
- Collegium Pharmaceutical, Inc.$460
- Sentynl Therapeutics, Inc.$225
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$218
- Scilex Pharmaceuticals Inc.$209
- Amgen$202
- plus $988 from 19 others
What the payments were for
- Food & beverage$4,600100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| IBSA Pharma Inc. | 120 | $2,318 |
| Collegium Pharmaceutical, Inc. | 36 | $460 |
| Sentynl Therapeutics, Inc. | 19 | $225 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $218 |
| Scilex Pharmaceuticals Inc. | 18 | $209 |
| Amgen(2 entities) | 10 | $202 |
| AbbVie | 9 | $187 |
| Virtus Pharmaceuticals LLC | 7 | $144 |
| Boston Scientific | 5 | $116 |
| Vertex | 3 | $73 |
| Indivior Inc. | 3 | $73 |
| Pfizer | 3 | $72 |
| Hikma Pharmaceuticals USA | 3 | $68 |
| Daiichi Sankyo Inc. | 2 | $45 |
| GRT US Holding, Inc. | 1 | $32 |
| Fidia Pharma USA Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $21 |
| Biodelivery Sciences International, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $15 |
| Medtronic | 1 | $15 |
| Electronic Waveform Lab, Inc. | 2 | $15 |
| Tonix Medicines, Inc. | 1 | $15 |
| USWM, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,621 in reported general payments places this provider in the 85th percentile of 830 physical medicine & rehabilitation providers in California.
See all physical medicine & rehabilitation providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 582 | $90,993 |
| Levorphanol Tartrate | 35 | $60,767 |
| BelbucaBuprenorphine Hcl | 78 | $54,478 |
| NucyntaTapentadol Hcl | 65 | $53,659 |
| LicartDiclofenac Epolamine | 63 | $48,405 |
| PennsaidDiclofenac Sodium | 14 | $35,008 |
| Diclofenac Epolamine | 33 | $21,610 |
| OxycontinOxycodone Hcl | 44 | $16,866 |
| Nucynta ErTapentadol Hcl | 17 | $15,929 |
| Buprenorphine | 69 | $14,377 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 65 | $13,054 |
| MovantikNaloxegol Oxalate | 21 | $9,583 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 431 | $7,785 |
| Xtampza ErOxycodone Myristate | 20 | $7,689 |
| Pregabalin | 257 | $7,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Nucynta Er, Xtampza Er | $460 | $131,755180 claims |
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $144 | $60,76735 claims |
| IBSA Pharma Inc.Licart | $2,318 | $48,40563 claims |
| AmgenPennsaid | $202 | $35,00814 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Buprenorphine Hcl, Morphine Sulfate | $68 | $30,129228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 830 physical medicine & rehabilitation providers in California.
Other physical medicine & rehabilitation in Encino
- Ziyad AyyoubParamount$1.8M
- John ShenFontana$1.3M
- Andrew SkalskySan Diego$463K
- Nanette JoyceSacramento$237K
- Mary OatesSanta Maria$158K
- Jeryl WiensFresno$125K
- Pratik GandhiAnaheim$122K
- Ronald SchillingLong Beach$113K
- Kevin BarretteSan Francisco$84K
- Jeffrey ChenSan Diego$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.